Published in J Extracell Vesicles on February 28, 2017
High Vitamin D Levels May Downregulate Inflammation in Patients with Behçet's Disease. Int J Inflam (2017) 0.75
Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet (1990) 19.57
Membrane vesicles as conveyors of immune responses. Nat Rev Immunol (2009) 14.72
Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol (2006) 13.29
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Shedding microvesicles: artefacts no more. Trends Cell Biol (2009) 8.84
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest (1999) 3.19
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
Membrane microparticles: two sides of the coin. Physiology (Bethesda) (2005) 2.68
Microparticles in cardiovascular diseases. Cardiovasc Res (2003) 2.62
Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol (2003) 1.84
A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol (2012) 1.79
The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol (2009) 1.78
Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol (2002) 1.74
Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 1.73
The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A (2005) 1.71
Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum (2002) 1.67
Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther (2009) 1.61
Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J Biol Chem (1998) 1.57
Plasma microparticles and vascular disorders. Br J Haematol (2007) 1.52
Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum (2002) 1.47
Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One (2011) 1.39
Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity (2006) 1.38
Elevated plasma endothelial microparticles in multiple sclerosis. Neurology (2001) 1.38
Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol (2007) 1.37
Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology (Oxford) (2006) 1.35
Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol (1998) 1.29
Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther (2005) 1.28
Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum (2004) 1.25
The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp Cell Res (2008) 1.24
Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol (2013) 1.15
Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37. Front Microbiol (2011) 1.14
Behçet's syndrome. Curr Rheumatol Rep (2010) 1.10
The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum (2008) 1.08
Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol (2006) 1.03
The release of microparticles by RAW 264.7 macrophage cells stimulated with TLR ligands. J Leukoc Biol (2010) 1.02
Behçet's syndrome. Rheum Dis Clin North Am (2013) 0.99
LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol (2009) 0.96
Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis (2009) 0.91
Antifungal action of human cathelicidin fragment (LL13-37) on Candida albicans. Peptides (2011) 0.91
Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology (Oxford) (2010) 0.90
Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol (2014) 0.90
Behçet's syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med (2014) 0.87
The release of microparticles by Jurkat leukemia T cells treated with staurosporine and related kinase inhibitors to induce apoptosis. Apoptosis (2010) 0.85
The antimicrobial peptide LL-37 binds to the human plasma protein apolipoprotein A-I. Rapid Commun Mass Spectrom (2004) 0.85
Endothelial microparticles and the diagnosis of the vasculitides. Intern Med (2004) 0.84
The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Scand J Immunol (2013) 0.84
Salivary levels of antimicrobial peptides Hnp 1-3, Ll-37 and S100 in Behcet's disease. Arch Oral Biol (2011) 0.84
Raised endothelial microparticles an early marker for multiple sclerosis? Lancet (2001) 0.80
Biotherapies in Behçet's disease. Autoimmun Rev (2014) 0.78
Plasma exchange in the therapy of Behçet's disease. Graefes Arch Clin Exp Ophthalmol (1989) 0.78